Recent News

• 10.06.2025 - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
• 10.06.2025 - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
• 08.12.2025 - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.12.2025 - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 8-K Current report
• 09.04.2025 - EX-99.1 EX-99.1
• 08.22.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 8-K Current report
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.01.2025 - 8-K Current report
• 07.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]